Report Detail
Global Opioid-Induced Constipation Market Insights, Forecast to 2025
- RnM2327936 |
- 08 April, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
The global Opioid-Induced Constipation market is valued at 2240 million US$ in 2018 and will reach 3060 million US$ by the end of 2025, growing at a CAGR of 4.6% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Opioid-Induced Constipation market based on company, product type, end user and key regions.
This report studies the global market size of Opioid-Induced Constipation in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Opioid-Induced Constipation in these regions.
This research report categorizes the global Opioid-Induced Constipation market by top players/brands, region, type and end user. This report also studies the global Opioid-Induced Constipation market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Market size by Product
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Market size by End User
Hospital
Pharmacy
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Opioid-Induced Constipation market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Opioid-Induced Constipation companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Opioid-Induced Constipation submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Opioid-Induced Constipation are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Opioid-Induced Constipation market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Opioid-Induced Constipation Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Opioid-Induced Constipation Market Size Growth Rate by Product
- 1.4.2 Methylnaltrexone Bromide
- 1.4.3 Lubiprostone
- 1.4.4 Naloxegol
- 1.4.5 Others
- 1.5 Market by End User
- 1.5.1 Global Opioid-Induced Constipation Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Pharmacy
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Opioid-Induced Constipation Market Size
- 2.1.1 Global Opioid-Induced Constipation Revenue 2014-2025
- 2.1.2 Global Opioid-Induced Constipation Sales 2014-2025
- 2.2 Opioid-Induced Constipation Growth Rate by Regions
- 2.2.1 Global Opioid-Induced Constipation Sales by Regions
- 2.2.2 Global Opioid-Induced Constipation Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Opioid-Induced Constipation Sales by Manufacturers
- 3.1.1 Opioid-Induced Constipation Sales by Manufacturers
- 3.1.2 Opioid-Induced Constipation Sales Market Share by Manufacturers
- 3.1.3 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI)
- 3.2 Opioid-Induced Constipation Revenue by Manufacturers
- 3.2.1 Opioid-Induced Constipation Revenue by Manufacturers (2014-2019)
- 3.2.2 Opioid-Induced Constipation Revenue Share by Manufacturers (2014-2019)
- 3.3 Opioid-Induced Constipation Price by Manufacturers
- 3.4 Opioid-Induced Constipation Manufacturing Base Distribution, Product Types
- 3.4.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Opioid-Induced Constipation Product Type
- 3.4.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Opioid-Induced Constipation Sales by Product
- 4.2 Global Opioid-Induced Constipation Revenue by Product
- 4.3 Opioid-Induced Constipation Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Opioid-Induced Constipation Breakdown Data by End User
6 North America
- 6.1 North America Opioid-Induced Constipation by Countries
- 6.1.1 North America Opioid-Induced Constipation Sales by Countries
- 6.1.2 North America Opioid-Induced Constipation Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Opioid-Induced Constipation by Product
- 6.3 North America Opioid-Induced Constipation by End User
7 Europe
- 7.1 Europe Opioid-Induced Constipation by Countries
- 7.1.1 Europe Opioid-Induced Constipation Sales by Countries
- 7.1.2 Europe Opioid-Induced Constipation Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Opioid-Induced Constipation by Product
- 7.3 Europe Opioid-Induced Constipation by End User
8 Asia Pacific
- 8.1 Asia Pacific Opioid-Induced Constipation by Countries
- 8.1.1 Asia Pacific Opioid-Induced Constipation Sales by Countries
- 8.1.2 Asia Pacific Opioid-Induced Constipation Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Opioid-Induced Constipation by Product
- 8.3 Asia Pacific Opioid-Induced Constipation by End User
9 Central & South America
- 9.1 Central & South America Opioid-Induced Constipation by Countries
- 9.1.1 Central & South America Opioid-Induced Constipation Sales by Countries
- 9.1.2 Central & South America Opioid-Induced Constipation Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Opioid-Induced Constipation by Product
- 9.3 Central & South America Opioid-Induced Constipation by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Opioid-Induced Constipation by Countries
- 10.1.1 Middle East and Africa Opioid-Induced Constipation Sales by Countries
- 10.1.2 Middle East and Africa Opioid-Induced Constipation Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Opioid-Induced Constipation by Product
- 10.3 Middle East and Africa Opioid-Induced Constipation by End User
11 Company Profiles
- 11.1 Takeda Pharmaceuticals
- 11.1.1 Takeda Pharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
- 11.1.5 Takeda Pharmaceuticals Recent Development
- 11.2 Bayer
- 11.2.1 Bayer Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Bayer Opioid-Induced Constipation Products Offered
- 11.2.5 Bayer Recent Development
- 11.3 Sanofi
- 11.3.1 Sanofi Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Sanofi Opioid-Induced Constipation Products Offered
- 11.3.5 Sanofi Recent Development
- 11.4 Mallinckrodt
- 11.4.1 Mallinckrodt Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Mallinckrodt Opioid-Induced Constipation Products Offered
- 11.4.5 Mallinckrodt Recent Development
- 11.5 Salix (Bausch Health)
- 11.5.1 Salix (Bausch Health) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
- 11.5.5 Salix (Bausch Health) Recent Development
- 11.6 AstraZeneca
- 11.6.1 AstraZeneca Company Details
- 11.6.2 Company Business Overview
- 11.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 AstraZeneca Opioid-Induced Constipation Products Offered
- 11.6.5 AstraZeneca Recent Development
- 11.7 Progenics Pharmaceuticals
- 11.7.1 Progenics Pharmaceuticals Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
- 11.7.5 Progenics Pharmaceuticals Recent Development
- 11.8 Purdue Pharm
- 11.8.1 Purdue Pharm Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Purdue Pharm Opioid-Induced Constipation Products Offered
- 11.8.5 Purdue Pharm Recent Development
- 11.9 Nektar Therapeutics
- 11.9.1 Nektar Therapeutics Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Nektar Therapeutics Opioid-Induced Constipation Products Offered
- 11.9.5 Nektar Therapeutics Recent Development
- 11.10 Daiichi Sankyo
- 11.10.1 Daiichi Sankyo Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Daiichi Sankyo Opioid-Induced Constipation Products Offered
- 11.10.5 Daiichi Sankyo Recent Development
- 11.11 Prestige
- 11.12 GSK
- 11.13 Shionogi
12 Future Forecast
- 12.1 Opioid-Induced Constipation Market Forecast by Regions
- 12.1.1 Global Opioid-Induced Constipation Sales Forecast by Regions 2019-2025
- 12.1.2 Global Opioid-Induced Constipation Revenue Forecast by Regions 2019-2025
- 12.2 Opioid-Induced Constipation Market Forecast by Product
- 12.2.1 Global Opioid-Induced Constipation Sales Forecast by Product 2019-2025
- 12.2.2 Global Opioid-Induced Constipation Revenue Forecast by Product 2019-2025
- 12.3 Opioid-Induced Constipation Market Forecast by End User
- 12.4 North America Opioid-Induced Constipation Forecast
- 12.5 Europe Opioid-Induced Constipation Forecast
- 12.6 Asia Pacific Opioid-Induced Constipation Forecast
- 12.7 Central & South America Opioid-Induced Constipation Forecast
- 12.8 Middle East and Africa Opioid-Induced Constipation Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Opioid-Induced Constipation Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Opioid-Induced Constipation. Industry analysis & Market Report on Opioid-Induced Constipation is a syndicated market report, published as Global Opioid-Induced Constipation Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Opioid-Induced Constipation market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
